Search Results - "Cinquino, Aileen"

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC by Evans, Rachel, Lee, Kelvin, Wallace, Paul K., Reid, Mary, Muhitch, Jason, Dozier, Askia, Mesa, Circe, Luaces, Patricia L., Santos-Morales, Orestes, Groman, Adrienne, Cedeno, Carlos, Cinquino, Aileen, Fisher, Daniel T., Puzanov, Igor, Opyrchal, Mateusz, Fountzilas, Christos, Dai, Tong, Ernstoff, Marc, Attwood, Kristopher, Hutson, Alan, Johnson, Candace, Mazorra, Zaima, Saavedra, Danay, Leon, Kalet, Lage, Agustin, Crombet, Tania, Dy, Grace K.

“…BackgroundCIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown survival benefit as a switch maintenance treatment after…”
Get full text

Abstract CT130: Evidence for synergistic immune responses in the first-in-human (FIH) combination of B cell-activating immunotherapy (IO) with anti-PD1 immune checkpoint inhibitor nivolumab (N) as 2nd-line therapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC) by Crombet, Tania, Muhitch, Jason, Mesa, Circe, Evans, Rachel, Hernandez, Danay S., Luaces, Patricia L., Mazorra, Zaima, Morales, Orestes, Cedeno, Carlos, Cinquino, Aileen, Fisher, Daniel T., Lee, Kelvin, Reid, Mary, Dy, Grace

“…Introduction: While combined immunotherapeutic activation of B and T cells is predicted to synergistically enhance both humoral and cell-mediated immunity,…”
Get full text

Abstract CT088: Final results of the Phase I study of nivolumab in combination with CIMAvax, an epidermal growth factor(EGF)-depleting immunotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Focus on biomarker analyses by Dy, Grace K., Lee, Kelvin, Groman, Adrienne, Cinquino, Aileen, Cedeno, Carlos, Minderman, Hans, Hutson, Alan, Wallace, Paul, Johnson, Candace, Mazorra, Zaima, Hernandez, Danay Saavedra, Leon, Kalet, Lage, Agustin, Crombet, Tania

“…BACKGROUND: The combination of nivolumab with CIMAvax is safe and can be administered together at the approved dosage of each agent administered as…”
Get full text